Merck & Co. has penned a $300 million biobucks-per-product deal with cancer biotech Epitopea to identify previously secret ...

Epitopea, a transatlantic cancer immunotherapeutics company developing accessible, off-the-shelf RNA-based immunotherapies, announces a license and research collaboration agreement with MSD (tradename ...

South Korea-based Hanmi Pharmaceutical has reported positive outcomes from a Phase I/II clinical trial of Tivumecirnon ...

The EC has conditionally approved MSD's Welireg as a single agent for the treatment of adults with VHL disease and advanced ...

Hanmi Pharmaceutical confirms positive results for Tibumeshirnon and Keytruda in cancer trial Phase 2 trial highlights ...

MSD Pharmaceuticals and Delhi Capitals have partnered to raise cervical cancer prevention awareness in India. The women's T20 team will display this message on their jerseys during matches. The ...

MSK plans to speed up early-stage drug development by using AWS Drug Discovery Workbench to screen potential candidates.

Big Tech and pharmaceutical companies are accelerating the implementation of artificial intelligence in the healthcare ...

This is a 20% increase from the previous year. It indicates that investments in the pharmaceutical sector are increasingly concentrated in China. U.S. company Merck (MSD) signed an exclusive license ...

MSD Ireland's robust R&D pipeline of therapeutic projects ensures it is ready to meet the diverse needs of patients globally ...

Kelun-Biotech has become the second drugmaker to ... Daiichi's was re-filed for EGFR-positive NSCLC only. Outside China, MSD has rights to sac-TMT under the terms of a partnership signed in ...

Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced that the European Commission (EC) has conditionally approved WELIREG® (belzutifan), Merck’s oral ...